These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 26428226)
1. iPSC-based drug screening for Huntington's disease. Zhang N; Bailus BJ; Ring KL; Ellerby LM Brain Res; 2016 May; 1638(Pt A):42-56. PubMed ID: 26428226 [TBL] [Abstract][Full Text] [Related]
2. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H Mol Brain; 2012 May; 5():17. PubMed ID: 22613578 [TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy. Liu L; Huang JS; Han C; Zhang GX; Xu XY; Shen Y; Li J; Jiang HY; Lin ZC; Xiong N; Wang T Mol Neurobiol; 2016 Dec; 53(10):6698-6708. PubMed ID: 26659595 [TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310 [TBL] [Abstract][Full Text] [Related]
5. Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy. Csobonyeiova M; Polak S; Danisovic L Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32213859 [TBL] [Abstract][Full Text] [Related]
14. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology. Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692 [TBL] [Abstract][Full Text] [Related]
15. Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics. Akimov SS; Jiang M; Kedaigle AJ; Arbez N; Marque LO; Eddings CR; Ranum PT; Whelan E; Tang A; Wang R; DeVine LR; Talbot CC; Cole RN; Ratovitski T; Davidson BL; Fraenkel E; Ross CA Hum Mol Genet; 2021 Nov; 30(24):2469-2487. PubMed ID: 34296279 [TBL] [Abstract][Full Text] [Related]
16. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. HD iPSC Consortium Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968 [TBL] [Abstract][Full Text] [Related]
17. Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery. Kunkanjanawan T; Carter R; Ahn KS; Yang J; Parnpai R; Chan AWS SLAS Discov; 2017 Jul; 22(6):696-705. PubMed ID: 28027448 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic alterations mediate iPSC-induced normalization of DNA repair gene expression and TNR stability in Huntington's disease cells. Mollica PA; Zamponi M; Reid JA; Sharma DK; White AE; Ogle RC; Bruno RD; Sachs PC J Cell Sci; 2018 Jul; 131(13):. PubMed ID: 29898922 [TBL] [Abstract][Full Text] [Related]
19. Generation of induced pluripotent stem cell line ICGi018-A from peripheral blood mononuclear cells of a patient with Huntington's disease. Malakhova AA; Grigor'eva EV; Malankhanova TB; Pavlova SV; Valetdinova KR; Abramycheva NY; Vetchinova AS; Illarioshkin SN; Zakian SM Stem Cell Res; 2020 Apr; 44():101743. PubMed ID: 32179492 [TBL] [Abstract][Full Text] [Related]
20. Generation of an induced pluripotent stem cell line from a Huntington's disease patient with a long HTT-PolyQ sequence. Miller DC; Lisowski P; Genehr C; Wanker EE; Priller J; Prigione A; Diecke S Stem Cell Res; 2023 Apr; 68():103056. PubMed ID: 36863131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]